US2020060976A1PendingUtilityA1

Formulations of enzalutamide

Assignee: ASTELLAS PHARMA INCPriority: Sep 11, 2012Filed: Apr 1, 2019Published: Feb 27, 2020

Est. expirySep 11, 2032(~6.1 yrs left)· nominal 20-yr term from priority

Inventors:Douglas Alan Lorenz Sanjay Konagurthu Randy J. Wald Jason A. Everett Sheila Matz Yuuki Takaishi Toshiro Sakai Ryousuke Irie Shinsuke Oba Hiroyasu Toyota Koji Nishimura Atsushi Kanbayashi

A61P 43/00A61P 35/00A61K 9/1652A61P 15/14A61P 15/08A61P 15/00A61P 13/08A61K 31/4164C07D 233/86A61K 9/2054A61K 9/10A61K 9/2095A61K 47/32A61K 9/16A61K 31/4166A61K 47/38A61K 9/2027A61K 9/146A61K 9/1635

PatentIndex Score

Cited by

References

Claims

Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Claims

exact text as granted — not AI-modified

1 - 82 . (canceled) 
     
     
         83 . A solid pharmaceutical composition comprising a solid dispersion containing amorphous enzalutamide and a polymer, wherein the polymer is hydroxypropyl methylcellulose acetate succinate. 
     
     
         84 - 86 . (canceled) 
     
     
         87 . The solid pharmaceutical composition according to  claim 83 , wherein the amount of the polymer is 0.5 to 7 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         88 . The solid pharmaceutical composition according to  claim 83 , wherein the amount of the polymer is 0.5 to 3 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         89 . The solid pharmaceutical composition according to  claim 83 , wherein the amount of the polymer is 3 to 5 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         90 . The solid pharmaceutical composition according to  claim 83 , wherein the amount of the polymer is 3 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         91 . The solid pharmaceutical composition according to  claim 83 , wherein the amount of the polymer is 5 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         92 . The solid pharmaceutical composition according to  claim 83 , which the solubility of enzalutamide is twice or more compared to that of enzalutamide. 
     
     
         93 - 95 . (canceled) 
     
     
         96 . The solid pharmaceutical composition according to  claim 83 , which is a tablet.

Join the waitlist — get patent alerts

Track US2020060976A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.